High expression of the hypoxia marker CAIX in soft tissue sarcoma was found to be associated with poor survival in the Phase III adjuvant RT VorteX trial but two other hypoxia markers Hif-1a and GLUT1 were not (Forker et al., 2018). This evidence concerns the gene CA9 and soft tissue sarcoma.